Research & Literature

Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome.

Geisler BP, Raad RA, Esaian D, et al.

Journal for immunotherapy of cancer 2015; (3()):4 doi:10.1186/s40425-015-0048-2.

[Cardiac involvement in Churg-Strauss syndrome].

Brucato A, Maestroni S, Masciocco G, et al.

Giornale italiano di cardiologia (2006) 2015; (16(9)):493-500 doi:10.1714/1988.21524.

[Endomyocardial biopsy should be performed in selected patients with suspected myocarditis].

Ammirati E, Cipriani M, Bonacina E, et al.

Giornale italiano di cardiologia (2006) 2015; (16(10)):539-43 doi:10.1714/2028.22034.

Viral myocarditis.

Rose NR

Current opinion in rheumatology 2016; (28(4)):383-9 doi:10.1097/BOR.0000000000000303.

Noninvasive Contrast-Enhanced Ultrasound Molecular Imaging Detects Myocardial Inflammatory Response in Autoimmune Myocarditis.

Steinl DC, Xu L, Khanicheh E, et al.

Circulation. Cardiovascular imaging 2016; (9(8)).

Incidence, Risk Factors, and Outcome of Life-Threatening Ventricular Arrhythmias in Giant Cell Myocarditis.

Ekström K, Lehtonen J, Kandolin R, et al.

Circulation. Arrhythmia and electrophysiology 2016; (9(12)).

Cardiac involvement in DRESS syndrome.

Thongsri T, Chularojanamontri L, Pichler WJ

Asian Pacific journal of allergy and immunology 2017; (35(1)):3-10 doi:10.12932/AP0847.

Lupus Myocarditis: Initial Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients.

Thomas G, Cohen Aubart F, Chiche L, et al.

The Journal of rheumatology 2017; (44(1)):24-32 doi:10.3899/jrheum.160493.

Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy.

Diny NL, Baldeviano GC, Talor MV, et al.

The Journal of experimental medicine 2017; (214(4)):943-957 doi:10.1084/jem.20161702.

What to do when you question cardiac troponin values.

Mair J, Lindahl B, Müller C, et al.

European heart journal. Acute cardiovascular care 2018; (7(6)):577-586 doi:10.1177/2048872617708973.

Cardiac Autoimmunity: Myocarditis.

Bracamonte-Baran W, Čiháková D

Advances in experimental medicine and biology 2017; (1003()):187-221 doi:10.1007/978-3-319-57613-8_10.

Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.

Tay RY, Blackley E, McLean C, et al.

British journal of cancer 2017; (117(7)):921-924 doi:10.1038/bjc.2017.253.

Inflammatory Cardiomyopathic Syndromes.

Trachtenberg BH, Hare JM

Circulation research 2017; (121(7)):803-818 doi:10.1161/CIRCRESAHA.117.310221.

Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes.

Brambatti M, Matassini MV, Adler ED, et al.

Journal of the American College of Cardiology 2017; (70(19)):2363-2375 doi:10.1016/j.jacc.2017.09.023.

Smoldering myocarditis following immune checkpoint blockade.

Norwood TG, Westbrook BC, Johnson DB, et al.

Journal for immunotherapy of cancer 2017; (5(1)):91 doi:10.1186/s40425-017-0296-4.

Eosinophilic Myocarditis.

Cheung CC, Constantine M, Ahmadi A, et al.

The American journal of the medical sciences 2017; (354(5)):486-492 doi:10.1016/j.amjms.2017.04.002.

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Mahmood SS, Fradley MG, Cohen JV, et al.

Journal of the American College of Cardiology 2018; (71(16)):1755-1764 doi:10.1016/j.jacc.2018.02.037.

Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area.

Mir H, Alhussein M, Alrashidi S, et al.

The Canadian journal of cardiology 2018; (34(8)):1059-1068 doi:10.1016/j.cjca.2018.03.012.

Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis.

Meyer IS, Goetzke CC, Kespohl M, et al.

Frontiers in immunology 2018; (9()):2303 doi:10.3389/fimmu.2018.02303.

Monomorphic Ventricular Tachycardia as a Presentation of Giant Cell Myocarditis.

Chiu MH, Trpkov C, Rezazedeh S, Chew DS

Case reports in cardiology 2019; (2019()):7276516 doi:10.1155/2019/7276516.

Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review.

Pradhan R, Nautiyal A, Singh S

International journal of cardiology 2019; (296()):113-121 doi:10.1016/j.ijcard.2019.07.025.

Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas.

Pinkert S, Pryshliak M, Pappritz K, et al.

Cardiovascular research 2020; (116(10)):1756-1766 doi:10.1093/cvr/cvz259.

A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies.

Guo CW, Alexander M, Dib Y, et al.

European journal of cancer (Oxford, England : 1990) 2020; (124()):15-24 doi:10.1016/j.ejca.2019.09.009.

[Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].

Prevel R, Colin G, Calès V, et al.

La Revue de medecine interne 2020; (41(4)):284-288 doi:10.1016/j.revmed.2019.12.023.

Clinical Characteristics and Prognostic Factors of Myocarditis in New Zealand Patients.

Wong BTW, Christiansen JP

Heart, lung & circulation 2020; (29(8)):1139-1145 doi:10.1016/j.hlc.2020.01.007.

A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.

Wang F, Sun X, Qin S, et al.

Chinese clinical oncology 2020; (9(2)):16 doi:10.21037/cco.2020.03.08.

Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.

Peleg Hasson S, Salwen B, Sivan A, et al.

Clinical research in cardiology : official journal of the German Cardiac Society 2021; (110(1)):50-60 doi:10.1007/s00392-020-01648-3.

Therapeutic strategies for virus-negative myocarditis: a comprehensive review.

De Luca G, Campochiaro C, Sartorelli S, et al.

European journal of internal medicine 2020; (77()):9-17 doi:10.1016/j.ejim.2020.04.050.

Single-Cell RNA Sequencing to Dissect the Immunological Network of Autoimmune Myocarditis.

Hua X, Hu G, Hu Q, et al.

Circulation 2020; (142(4)):384-400 doi:10.1161/CIRCULATIONAHA.119.043545.

Update on acute myocarditis.

Ammirati E, Veronese G, Bottiroli M, et al.

Trends in cardiovascular medicine 2021; (31(6)):370-379 doi:10.1016/j.tcm.2020.05.008.

Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.

Michel L, Totzeck M, Lehmann L, Finke D

Herz 2020; (45(7)):645-651 doi:10.1007/s00059-020-04954-8.

Viral myocarditis involves the generation of autoreactive T cells with multiple antigen specificities that localize in lymphoid and non-lymphoid organs in the mouse model of CVB3 infection.

Basavalingappa RH, Arumugam R, Lasrado N, et al.

Molecular immunology 2020; (124()):218-228 doi:10.1016/j.molimm.2020.06.017.

Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.

Ammirati E, Frigerio M, Adler ED, et al.

Circulation. Heart failure 2020; (13(11)):e007405 doi:10.1161/CIRCHEARTFAILURE.120.007405.

A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.

Wei SC, Meijers WC, Axelrod ML, et al.

Cancer discovery 2021; (11(3)):614-625 doi:10.1158/2159-8290.CD-20-0856.

Outcomes of Mechanical Circulatory Support for Giant Cell Myocarditis: A Systematic Review.

Patel PM, Saxena A, Wood CT, et al.

Journal of clinical medicine 2020; (9(12)) doi:10.3390/jcm9123905.

Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy-case report.

Schiopu SRI, Käsmann L, Schönermarck U, et al.

Translational lung cancer research 2021; (10(2)):1039-1046 doi:10.21037/tlcr-20-1095.

Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis.

Thavendiranathan P, Zhang L, Zafar A, et al.

Journal of the American College of Cardiology 2021; (77(12)):1503-1516 doi:10.1016/j.jacc.2021.01.050.

The State of the Heart Biopsy: A Clinical Review.

Kiamanesh O, Toma M

CJC open 2021; (3(4)):524-531 doi:10.1016/j.cjco.2020.11.017.

Patients with acute myocarditis and preserved systolic left ventricular function: comparison of global and regional longitudinal strain imaging by echocardiography with quantification of late gadolinium enhancement by CMR.

Meindl C, Paulus M, Poschenrieder F, et al.

Clinical research in cardiology : official journal of the German Cardiac Society 2021; (110(11)):1792-1800 doi:10.1007/s00392-021-01885-0.

Myopericarditis in children and adolescent: is the elevated troponin and chest pain as alarming as we thought?

Başar EZ, Borakay D, Akalın F

Cardiology in the young 2022; (32(3)):420-424 doi:10.1017/S1047951121002304.

Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment.

Wang C, Lin J, Wang Y, et al.

Frontiers in pharmacology 2021; (12()):770631 doi:10.3389/fphar.2021.770631.

Myocarditis in systemic immune-mediated diseases: Prevalence, characteristics and prognosis. A systematic review.

Cheng CY, Baritussio A, Giordani AS, et al.

Autoimmunity reviews 2022; (21(4)):103037 doi:10.1016/j.autrev.2022.103037.

Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor-induced Myocarditis.

Cadour F, Cautela J, Rapacchi S, et al.

Radiology 2022; (303(3)):512-521 doi:10.1148/radiol.211765.

[Ten questions about eosinophilic myocarditis].

Pagura L, Imazio M, Merlo M, Sinagra G

Giornale italiano di cardiologia (2006) 2022; (23(4)):259-267 doi:10.1714/3766.37535.

Cardiac Magnetic Resonance Imaging in Immune Check-Point Inhibitor Myocarditis: A Systematic Review.

Arcari L, Tini G, Camastra G, et al.

Journal of imaging 2022; (8(4)) doi:10.3390/jimaging8040099.

The prognostic value of global myocardium strain by CMR-feature tracking in immune checkpoint inhibitor-associated myocarditis.

Zhao SH, Yun H, Chen CZ, et al.

European radiology 2022; (32(11)):7657-7667 doi:10.1007/s00330-022-08844-x.

Global longitudinal strain by CMR improves prognostic stratification in acute myocarditis presenting with normal LVEF.

Porcari A, Merlo M, Baggio C, et al.

European journal of clinical investigation 2022; (52(10)):e13815 doi:10.1111/eci.13815.

Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis.

Cau R, Solinas C, De Silva P, et al.

International journal of cancer 2022; (151(11)):1860-1873 doi:10.1002/ijc.34169.

Natural History of Myocardial Injury After COVID-19 Vaccine-Associated Myocarditis.

Mustafa Alhussein M, Rabbani M, Sarak B, et al.

The Canadian journal of cardiology 2022; (38(11)):1676-1683 doi:10.1016/j.cjca.2022.07.017.

Electrocardiographic Features of Immune Checkpoint Inhibitor-Associated Myocarditis.

Song W, Zheng Y, Dong M, et al.

Current problems in cardiology 2023; (48(2)):101478 doi:10.1016/j.cpcardiol.2022.101478.

Myocardial Involvement in Systemic Autoimmune Rheumatic Diseases.

Zagouras AA, Tang WHW

Rheumatic diseases clinics of North America 2023; (49(1)):45-66 doi:10.1016/j.rdc.2022.08.002.

Severe coronary artery spasm after administration of a 5-hydroxytryptamine type 1 receptor agonist in a patient with new-onset Graves' disease and myocarditis after SARS-CoV2 vaccination.

Vandebosch C, Dupont M, Verhaert D, Mullens W

Acta cardiologica 2023; (78(8)):889-893 doi:10.1080/00015385.2022.2135224.

Multimodality Screening For (Peri)Myocarditis In Newly Diagnosed Idiopathic Inflammatory Myopathies: A Cross-Sectional Study.

Lim J, Walter HAW, de Bruin-Bon RACM, et al.

Journal of neuromuscular diseases 2023; (10(2)):185-197 doi:10.3233/JND-221582.

Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.

Salem JE, Bretagne M, Abbar B, et al.

Cancer discovery 2023; (13(5)):1100-1115 doi:10.1158/2159-8290.CD-22-1180.

Left atrial strain parameters derived by echocardiography are impaired in patients with acute myocarditis and preserved systolic left ventricular function.

Meindl C, Paulus M, Poschenrieder F, et al.

The international journal of cardiovascular imaging 2023; (39(6)):1157-1165 doi:10.1007/s10554-023-02827-9.

Fulminant Eosinophilic Myocarditis Without Peripheral Eosinophilia.

Lee JY, Lee SH, Kim WH

Texas Heart Institute journal 2023; (50(2)) doi:10.14503/THIJ-21-7818.

Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: A case report.

Wang C, Zhong B, He J, Liao X

Medicine 2023; (102(15)):e33550 doi:10.1097/MD.0000000000033550.

Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study.

Delombaerde D, De Sutter J, Croes L, et al.

Pharmaceuticals (Basel, Switzerland) 2023; (16(4)) doi:10.3390/ph16040625.

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series.

Coustal C, Vanoverschelde J, Quantin X, et al.

Journal for immunotherapy of cancer 2023; (11(5)) doi:10.1136/jitc-2022-004792.

Reverse takotsubo syndrome heralding as ventricular fibrillation: a case report.

Basnet A, Sharma NR, Lamichhane S, et al.

Annals of medicine and surgery (2012) 2023; (85(7)):3744-3747 doi:10.1097/MS9.0000000000000965.

Fatal Myopericarditis in a Patient With Lupus Erythematosus Supported by Extracorporeal Membrane Oxygenation: A Case Report.

Lee SY, Park JH, Shin DH, et al.

Journal of rheumatic diseases 2021; (28(3)):165-170 doi:10.4078/jrd.2021.28.3.165.

Myocarditis in connective tissue diseases: an often-overlooked clinical manifestation.

Azzam M, Awad A, Abugharbyeh A, Kahaleh B

Rheumatology international 2023; (43(11)):1983-1992 doi:10.1007/s00296-023-05428-w.

Usefulness of Longitudinal Strain to Assess Cancer Therapy-Related Cardiac Dysfunction and Immune Checkpoint Inhibitor-Induced Myocarditis.

Tamura Y, Tamura Y

Pharmaceuticals (Basel, Switzerland) 2023; (16(9)) doi:10.3390/ph16091297.

PD-1 inhibitors-associated myocarditis in non-small cell lung cancer patients.

He Y, Chen W, Cai J, et al.

Journal of thoracic disease 2023; (15(9)):4606-4619 doi:10.21037/jtd-23-596.

Fulminant myocarditis proven by early biopsy and outcomes.

Huang F, Ammirati E, Ponnaiah M, et al.

European heart journal 2023; (44(48)):5110-5124 doi:10.1093/eurheartj/ehad707.

Post-acute midterm follow-up cardiac MRI findings and clinical outcomes in patients with COVID-19 vaccine-associated myocarditis: a comprehensive systematic review and meta-analysis.

Samimisedeh P, Jafari Afshar E, Tayebi A, Rastad H

Infectious diseases (London, England) 2024; (56(3)):193-205 doi:10.1080/23744235.2023.2286289.

CD4+TEM cells drive the progression from acute myocarditis to dilated cardiomyopathy in CVB3-induced BALB/c mice.

Huang Y, Huang X, Wei Z, et al.

International immunopharmacology 2024; (127()):111304 doi:10.1016/j.intimp.2023.111304.

Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge.

Frascaro F, Bianchi N, Sanguettoli F, et al.

Journal of clinical medicine 2023; (12(24)) doi:10.3390/jcm12247737.

Activation of ETAR and ETBR in myocardial tissue characterizes heart failure induced by experimental autoimmune myocarditis.

Yang P, Wu Y, Li F, et al.

BMC cardiovascular disorders 2024; (24(1)):11 doi:10.1186/s12872-023-03658-1.

Myocarditis and Chronic Inflammatory Cardiomyopathy, from Acute Inflammation to Chronic Inflammatory Damage: An Update on Pathophysiology and Diagnosis.

Uccello G, Bonacchi G, Rossi VA, et al.

Journal of clinical medicine 2023; (13(1)) doi:10.3390/jcm13010150.

Corticosteroid-resistant immune-related adverse events: a systematic review.

Daetwyler E, Wallrabenstein T, König D, et al.

Journal for immunotherapy of cancer 2024; (12(1)) doi:10.1136/jitc-2023-007409.

Case Report: Temporary pacing using active fixation lead and invasive electrophysiology studies for immune checkpoint inhibitor associated reversible advanced atrioventricular block.

Wang Y, Qian M, Jin X, et al.

Frontiers in cardiovascular medicine 2024; (11()):1336609 doi:10.3389/fcvm.2024.1336609.

Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature.

Saad R, Ghaddar A, Zeenny RM

Journal of medical case reports 2024; (18(1)):107 doi:10.1186/s13256-024-04397-3.

Long-term efficacy and safety of tailored immunosuppressive therapy in immune-mediated biopsy-proven myocarditis: A propensity-weighted study.

Caforio ALP, Giordani AS, Baritussio A, et al.

European journal of heart failure 2024; (26(5)):1175-1185 doi:10.1002/ejhf.3220.

Autoimmune Myocarditis, Old Dogs and New Tricks.

Won T, Song EJ, Kalinoski HM, et al.

Circulation research 2024; (134(12)):1767-1790 doi:10.1161/CIRCRESAHA.124.323816.

Prospective cardiovascular events in patients with advanced thoracic cancer treated with immune checkpoint inhibitor.

Toublanc AC, Faure M, Verdy G, et al.

European journal of cancer (Oxford, England : 1990) 2024; (207()):114191 doi:10.1016/j.ejca.2024.114191.

Immunomodulating and Immunosuppressive Therapy for Virus-Negative Immune-Mediated Myocarditis.

Frustaci A, Letizia C, Alfarano M, et al.

Biomedicines 2024; (12(7)) doi:10.3390/biomedicines12071565.

Therapeutic agents for steroid-refractory immune checkpoint inhibitor-related myocarditis: a narrative review.

Wang Y, Li S, Shi H, et al.

Cardiovascular diagnosis and therapy 2024; (14(4)):679-697 doi:10.21037/cdt-24-114.

Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design.

Salem JE, Ederhy S, Belin L, et al.

Archives of cardiovascular diseases 2025; (118(2)):106-115 doi:10.1016/j.acvd.2024.12.005.

Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review.

Man X, Wang H, Chen C, et al.

Frontiers in immunology 2025; (16()):1455347 doi:10.3389/fimmu.2025.1455347.

Characterization of Cardiovascular Events and Prognosis in Immune Checkpoint Inhibitor-Related Myocarditis.

Pereyra Pietri M, Farina JM, Scalia IG, et al.

Mayo Clinic proceedings 2025; (100(12)):2140-2151 doi:10.1016/j.mayocp.2024.12.017.

Diagnostic utility of the revised Lake Louise criteria in myocarditis associated with active autoimmune rheumatic disease.

Hua A, Domenech-Ximenos B, Lopez B, et al.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 2025; (27(2)):101916 doi:10.1016/j.jocmr.2025.101916.

Immune-Related Fulminant Myocarditis Revealed Using Myocardial Histopathology at Autopsy in the Treatment of Advanced Renal Cell Carcinoma: A Case Report.

Hayashi Y, Kawasaki Y, Katayama H, et al.

Case reports in oncology 2025; (18(1)):738-743 doi:10.1159/000546288.

Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management.

Becker RC

Journal of thrombosis and thrombolysis 2025; (58(8)):1021-1044 doi:10.1007/s11239-025-03146-7.

Fulminant myocarditis: outcome predictors in an international cohort study.

Majunke N, Haertel F, Binzenhöfer L, et al.

European heart journal 2025; doi:10.1093/eurheartj/ehaf671.

Immune checkpoint Inhibitor-Related Myocarditis: A Comprehensive Analysis of Clinical Manifestations and Prognostic Factors.

Fan Y, Xu Y, Liu X, et al.

The oncologist 2025; doi:10.1093/oncolo/oyaf285.

Giant Cell Myocarditis: An Updated Review of Pathogenesis, Clinical Presentation, and Modern Management Approaches.

Elattar S, Hassid Y, Cheikhali R, et al.

Cardiology in review 2025; doi:10.1097/CRD.0000000000001123.

Prognostic role of updated Lake Louise criteria for the diagnosis of acute myocarditis (ITAMY-mapping study).

Aquaro GD, Ianni U, Licordari R, et al.

International journal of cardiology 2026; (444()):134016 doi:10.1016/j.ijcard.2025.134016.

Evolution in the Diagnosis and Treatment of Myocarditis in Recent Years: State of the Art.

Campodonico J, Lauri C, Pezzuto B, et al.

Journal of clinical medicine 2025; (14(21)) doi:10.3390/jcm14217661.

Refractory ventricular arrhythmia in a patient with suspected immune checkpoint inhibitor-related myocarditis: a case report.

Jin X, Zheng R

European heart journal. Case reports 2025; (9(11)):ytaf540 doi:10.1093/ehjcr/ytaf540.

Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement.

Herrmann J, Barac A, Carver J, et al.

JAMA oncology 2025; doi:10.1001/jamaoncol.2025.4543.

How should immune checkpoint inhibitor myocarditis be treated?

Badaan S, Abbass A, Tov S, et al.

Cardio-oncology (London, England) 2025; (11(1)):108 doi:10.1186/s40959-025-00404-8.

Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.

Lu M, Muhetaer A, Su C, et al.

Frontiers in immunology 2025; (16()):1671964 doi:10.3389/fimmu.2025.1671964.

Fulminant Immune Checkpoint Inhibitor-Induced Myocarditis and Complete Heart Block in Advanced Melanoma: A Case Report.

Alhayek B, Malone X, Rashid MA, et al.

Cureus 2025; (17(11)):e98075 doi:10.7759/cureus.98075.

Cyclophosphamide-Induced Hemorrhagic Myocarditis.

Jibawi Rivera RR, Harmon DM, Herrmann J, Pellikka PA

JACC. Case reports 2026; (31(8)):106613 doi:10.1016/j.jaccas.2025.106613.

A case of immune-related adverse events, thyroid dysfunction, myocarditis with myositis, and myasthenia gravis overlap syndrome following serplulimab administration for lung adenocarcinoma.

Li X, Feng Q, Yu Y, et al.

Immunotherapy 2025; (17(17-18)):1241-1247 doi:10.1080/1750743X.2026.2619654.

Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact.

Mauriello A, Correra A, Maratea AC, et al.

Journal of clinical medicine 2026; (15(2)) doi:10.3390/jcm15020814.

Immune Mechanisms of Viral, Autoimmune, and Immune Checkpoint Inhibitor-Associated Myocarditis.

Jo W, Sun V, Čiháková D

Immunological reviews 2026; (338(1)):e70111 doi:10.1111/imr.70111.

Biopsy-proven myocarditis: peripheral immunophenotypes correlate with histology, etiology, immunosuppressive therapy.

Vicenzetto C, Giordani AS, Baritussio A, et al.

Journal of translational autoimmunity 2026; (12()):100355 doi:10.1016/j.jtauto.2026.100355.

Long COVID Myocarditis: Incidence, Mechanisms, Clinical Implications, and Management.

Dunde A, Maniyar P, Vora N, et al.

Cardiology in review 2026; doi:10.1097/CRD.0000000000001229.

Diagnostic and Therapeutic Options in Myocarditis and Inflammatory Cardiomyopathy.

Schultheiss HP, Escher F, Aleshcheva G, et al.

Biomedicines 2026; (14(3)) doi:10.3390/biomedicines14030691.

Diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis: A meta-analysis.

Lerchner T, Buehning F, Vogel J, et al.

European journal of cancer (Oxford, England : 1990) 2026; (239()):116693 doi:10.1016/j.ejca.2026.116693.

Premature diagnostic closure after pericarditis treatment delays recognition of ATTR cardiomyopathy: a multimodality case report.

Kocx CJ, Rolfe Z, Lattimore JD, Hunyor I

European heart journal. Case reports 2026; (10(5)):ytag310 doi:10.1093/ehjcr/ytag310.

Efficacy and safety of Songjiao Dihuang Tang decoction for the dynamic/adaptive treatment of immune checkpoint inhibitor-associated myocarditis: study protocol and statistical analysis plan for a stop&go, multicentre, randomized, parallel-controlled, double-blind, superiority clinical trial.

Long J, Zheng J, Jin Z, et al.

Frontiers in pharmacology 2026; (17()):1797368 doi:10.3389/fphar.2026.1797368.

Post-viral myocarditis.

Sokolski M, Zychla W, Wilk M, et al.

Heart failure reviews 2026; (31(1)).